LeMaitre Vascular, Inc. (LMAT)
| Market Cap | 2.46B |
| Revenue (ttm) | 249.60M |
| Net Income (ttm) | 57.73M |
| Shares Out | 22.78M |
| EPS (ttm) | 2.52 |
| PE Ratio | 42.93 |
| Forward PE | 37.48 |
| Dividend | $1.00 (0.92%) |
| Ex-Dividend Date | Mar 6, 2026 |
| Volume | 508,313 |
| Open | 111.69 |
| Previous Close | 113.69 |
| Day's Range | 105.85 - 112.74 |
| 52-Week Range | 71.42 - 115.33 |
| Beta | 0.71 |
| Analysts | Buy |
| Price Target | 106.50 (-1.55%) |
| Earnings Date | Feb 25, 2026 |
About LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter... [Read more]
Financial Performance
In 2025, LeMaitre Vascular's revenue was $249.60 million, an increase of 13.53% compared to the previous year's $219.86 million. Earnings were $57.73 million, an increase of 31.10%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $106.5, which is a decrease of -1.55% from the latest price.
News
LeMaitre Vascular: The Compounder Keeps Compounding
LeMaitre Vascular delivered strong Q4 and FY 2025 results, with 16% YoY sales growth and broad-based margin expansion. Artegraft's international rollout exceeded expectations, with 2025 sales doubling...
LeMaitre to Participate at Upcoming Investor Conferences in March
BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.
LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q4 2025 Earnings Call Transcript
LeMaitre Q4 2025 Financial Results
BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarter...
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 202...
Final Trade: LMAT, REGN, BA, TJX
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
LeMaitre Vascular, Inc. (LMAT) Q3 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. ( LMAT) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dorian LeBlanc - Chief Financial Officer George LeMaitre - Chairman & CEO David Roberts - Presi...
LeMaitre Q3 2025 Financial Results
BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarter...
LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, ...
LeMaitre Vascular: Investment Debate Remains In Place
LeMaitre Vascular remains a long-term compounder, delivering strong Q2 results with 15% sales growth, robust margins, and increased dividends. LMAT's investment thesis is supported by pricing power, a...
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in four upcoming investor conferences.
LeMaitre Vascular, Inc. (LMAT) Q2 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants David B. Roberts - President & Director Dorian LeBlanc - Chief Financial Officer ...
LeMaitre Q2 2025 Financial Results
BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarter...
LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025
BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, af...
Don't Be Too Cute, Buy These 3 Dividend Growers Instead
We avoid very high-yielding stocks, as the best way to grow richer over time is to own a diversified basket of dividend growth stocks. Today, we're highlighting a leading alternative asset manager, a ...
LeMaitre Vascular: Scaling Nicely As Global Demand Builds
LeMaitre's revenue and earnings continue to grow, though profit growth has moderated. The European launch of Artegraft and pending approval of XenoSure in China are key near-term catalysts. The portfo...
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference
BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare ...
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Q1 2025 Financial Results
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterl...
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025
BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, afte...
Small-Cap Dividend Stocks: Hidden Gems Or High-Risk Plays? - Top U.S. And Canadian Ones
Over the past decade, the iShares S&P/TSX SmallCap Index ETF has underperformed broader markets due to its heavy exposure to resource-heavy sectors like energy and materials. Acme's dividend track rec...
LeMaitre to Present at the 24th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tue...
Stocks Falling On Earnings - What To Do? February Dividend Income Report
Alimentation Couche-Tard has several growth vectors in place with a clear 5-year plan, including organic growth and growth by acquisition. Starting in March, I will increase my Smith Manoeuvre contrib...
Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors
GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ae...